Dr. Koneru is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2651 Discovery parkway
Bloomington, IN 47408Phone+1 812-918-5052Fax+1 812-918-5914
Education & Training
University of MarylandFellowship, Hematology and Medical Oncology, 1991 - 1993
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1987 - 1990
Osmania Medical College NTR UHSClass of 1982
Certifications & Licensure
IN State Medical License 1996 - 2025
IL State Medical License 1994 - 1999
MD State Medical License 1991 - 1994
NJ State Medical License 1988 - 1991- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer Start of enrollment: 2008 Jan 01
- Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma Start of enrollment: 2010 Oct 01
- First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Start of enrollment: 2010 Dec 01
Publications & Presentations
PubMed
- 2 citationsPhase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.Shadia I. Jalal, Nasser H. Hanna, Robin Zon, Gregory A. Masters, Hossein Borghaei
American Journal of Clinical Oncology. 2017-08-01 - 22 citationsSunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology GroupeJordan Schmitt, Scott R. Sommers, William E. Fisher, Rafat Ansari, Erwin Robin
Journal of Thoracic Oncology. 2012-04-01 - 40 citationsPaclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology GroupShadia I. Jalal, Pablo M. Bedano, Lawrence H. Einhorn, Sumeet Bhatia, Rafat Ansari
Journal of Thoracic Oncology. 2010-12-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
